Subscribe
dacian-g-shutterstock-com
Dacian G / Shutterstock.com
3 September 2015Americas

Bass suffers another IPR setback

Hedge fund manager Kyle Bass’s Coalition for Affordable Drugs has suffered another setback in its bid to knock out allegedly spurious patents after the US Patent and Trademark Office (USPTO) declined to institute an inter partes review (IPR) of a patent owned by Biogen.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
PTAB deals Bass another blow
21 October 2015   The Patent Trial and Appeal Board has rejected another inter partes review petition filed by hedge fund manager Kyle Bass’s organisation the Coalition for Affordable Drugs.
Americas
Bass set for first IPR trial as Shire petition proceeds
9 October 2015   Hedge fund manger Kyle Bass has secured his first inter partes review trial after the Patent Trial and Appeal Board instituted a challenge against a patent owned by biopharmaceutical company Shire.
Americas
Bass targets the University of Pennsylvania in IPR petitions
1 September 2015   Hedge fund manager Kyle Bass’s group the Coalition for Affordable Drugs has targeted two patents owned by the University of Pennsylvania in the latest petition for an inter partes review.


Editor's picks

UKIPO rejects Boehringer’s SPC for horse inhaler
Americas
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025

Editor's picks

Americas
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025
Americas
Bankruptcy judge approves $305m sale of genetics testing company
1 July 2025
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025
Europe
UPC confirms permanent injunction against Curio in 10x tech dispute
17 June 2025
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

More on this story

Americas
PTAB deals Bass another blow
21 October 2015   The Patent Trial and Appeal Board has rejected another inter partes review petition filed by hedge fund manager Kyle Bass’s organisation the Coalition for Affordable Drugs.
Americas
Bass set for first IPR trial as Shire petition proceeds
9 October 2015   Hedge fund manger Kyle Bass has secured his first inter partes review trial after the Patent Trial and Appeal Board instituted a challenge against a patent owned by biopharmaceutical company Shire.
Americas
Bass targets the University of Pennsylvania in IPR petitions
1 September 2015   Hedge fund manager Kyle Bass’s group the Coalition for Affordable Drugs has targeted two patents owned by the University of Pennsylvania in the latest petition for an inter partes review.

More on this story

Americas
PTAB deals Bass another blow
21 October 2015   The Patent Trial and Appeal Board has rejected another inter partes review petition filed by hedge fund manager Kyle Bass’s organisation the Coalition for Affordable Drugs.
Americas
Bass set for first IPR trial as Shire petition proceeds
9 October 2015   Hedge fund manger Kyle Bass has secured his first inter partes review trial after the Patent Trial and Appeal Board instituted a challenge against a patent owned by biopharmaceutical company Shire.
Americas
Bass targets the University of Pennsylvania in IPR petitions
1 September 2015   Hedge fund manager Kyle Bass’s group the Coalition for Affordable Drugs has targeted two patents owned by the University of Pennsylvania in the latest petition for an inter partes review.

More features

Startup challenges rival over brain monitoring tech at ITC
UKIPO rejects Boehringer’s SPC for horse inhaler
WilmerHale gains partner with ‘deep expertise’
Bayer, Orion take on Indian generic over $117bn drug
‘We created law’: G1/24 and the creation of the ‘diamond standard’
BMS unit loses cell therapy patent at European Patent Office
Amgen sues Biocon over blockbuster bone drugs as first biosimilars enter market
Lord Justice Birss to become chancellor of the High Court